Current Progress and Future Developments of Antibody Drug Conjugates
in Lung Cancer / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 468-476, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-939733
ABSTRACT
Antibody drug conjugates (ADCs) are a novel class of anti-cancer drugs, which combined the specificity of monoclonal antibodies with the cytotoxic palyload via the linkers. Many ADCs have not only verified impressive activity in a variety of cancers, including breast cancer and hematological system tumors, but also in lung cancer. The aim of this study was to provide informations for practice by summarizing the mechanism of action, clinical application and problems and challenges of ADCs.
.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Inmunoconjugados
/
Antineoplásicos Inmunológicos
/
Neoplasias Pulmonares
/
Anticuerpos Monoclonales
/
Neoplasias
/
Antineoplásicos
Límite:
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Lung Cancer
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS